ETBX-071

ImmunityBio, Inc. · Phase 2 active Small molecule

At a glance

Generic name	ETBX-071
Sponsor	ImmunityBio, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. (PHASE2)
Immunotherapy Before and After Surgery (PHASE2)
Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ETBX-071 CI brief — competitive landscape report
ETBX-071 updates RSS · CI watch RSS
ImmunityBio, Inc. portfolio CI